Emergent BioSolutions Inc., a specialty pharmaceutical company, develops and offers specialized products to healthcare providers and governments for use in addressing medical needs and emerging health threats. Divisions The company has two operating divisions, Biodefense and Biosciences. Biodefense The Biodefense division is a specialty pharmaceutical business focused on countermeasures that address CBRN (Chemical, Biological, Radiological and Nuclear) threats. The United States government is the primary purchaser of the company’s Biodefense products and often provides it with substantial funding for the development of its Biodefense product candidates. The company’s Biodefense portfolio consists of five revenue generating products, including BioThrax (Anthrax Vaccine Adsorbed), the only vaccine approved by the U.S. Food and Drug Administration, or the FDA, for the prevention of anthrax disease, as well as RSDL (decontamination lotion), three products it acquired in its acquisition of Cangene Corporation, which completed in February 2014, and various investigational stage product candidates. The company’s Biodefense division revenue generating products are BioThrax (Anthrax Vaccine Adsorbed); BAT (Botulism Antitoxin Heptavalent (A,B,C,D,E,F,G)-Equine); AIGIV (Anthrax Immune Globulin Intravenous (Human)); RSDL (decontamination lotion); and VIGIV (Vaccinia Immune Globulin Intravenous (Human)). The company’s Biodefense division investigational stage product candidates include: NuThrax (Anthrax Vaccine Adsorbed containing CPG 7909 Adjuvant), PreviThrax (Recombinant Protective Antigen Anthrax Vaccine, Purified), and other Biodefense product candidates. Operations that support this division include manufacturing, regulatory affairs, quality assurance, quality control, international sales and marketing, and domestic government affairs in support of the company’s marketed products, as well as product development and manufacturing infrastructure in support of its investigational stage product candidates. Biosciences The Biosciences division is a specialty pharmaceutical business focused on therapeutics and vaccines in hematology/oncology, transplantation and infectious disease. Its Biosciences portfolio consists of four revenue generating products, all four of which the company acquired in its acquisition of Cangene Corporation, as well as various investigational stage product candidates and a contract manufacturing services business. The company’s Biosciences division revenue generating products are WinRho SDF (Rho(D) Immune Globulin Intravenous (Human)); HepaGam B (Hepatitis B Immune Globulin Intravenous (Human)); VARIZIG (Varicella Zoster Immune Globulin (Human)); and episil. The company’s Biosciences division investigational stage product candidates include: otlertuzumab (Humanized Anti-CD37 therapeutic), IXINITY (trenonacog alfa), and other Biosciences product candidates. In addition, its Biosciences division includes various platform technologies, including its ADAPTI (modular protein technology) platform, its MVAtor (viral vaccine vector) platform, and its hyperimmune specialty plasma product manufacturing platform. Operations that support this division include manufacturing, quality, regulatory medical affairs, and sales and marketing in support of the company’s marketed products, as well as additional product development capabilities in support of its investigational stage product candidates. Strategy In 2012, the company announced a growth plan that presented its strategic, operational and financial goals to be achieved by the end of 2015. This growth plan is built on a strategy that focuses on expanding its reach in the biodefense market and diversifying into additional specialty markets. The company is building upon its position in biodefense, extending its track record of acquisitions, expanding and diversifying its biologics manufacturing expertise and continuing to partner with governments and non-governmental organizations. Research and Development The company’s total research and development expenditure was $119.9 million in 2013. Customers The company’s major customer includes Centers for Disease Control and Prevention, or CDC, an operating division of the U.S. Department of Health and Human Services. Competition The company’s competitors include Merck & Co., Inc.; GlaxoSmithKline plc; Sanofi Pasteur; Pfizer; Novartis AG; Pfizer Inc.; OSO BioPharmaceuticals Manufacturing, LLC; JHP Pharmaceuticals, LLC; Jubilant Hollister-Stier Laboratories LLC (a subsidiary of Jubilant Life Sciences Limited); Patheon Inc.; Hospira Inc.; Ajinomoto Althea, Inc. (a subsidiary of Ajinomoto Co., Inc.); Cook Pharmica LLC (a subsidiary of Cook Group Inc.); and Albany Molecular Research, Inc. Regulation The company’s status as a U.S. government contractor means that it is subject to various statutes and regulations, including the Federal Acquisition Regulation. Significant Events In August 2014, Emergent BioSolutions Inc.and MorphoSys AG announced an agreement for the joint development and commercialization of Emergent's preclinical bi-specific antibody, ES414, targeting prostate cancer. History The company was founded in 1998. It was incorporated in the state of Michigan in 1998 and subsequently reorganized as a Delaware corporation in 2004.
emergent biosolutions inc (EBS:New York)
2273 Research Boulevard
Rockville, MD 20850
|Albany Molecular Research Inc||$17.19 USD||+0.14|
|Bavarian Nordic A/S||kr211.50 DKK||+2.50|
|Depomed Inc||$22.99 USD||-0.07|
|Nektar Therapeutics||$12.94 USD||-0.09|
|Skyepharma PLC||299.25 GBp||-7.75|
|View Industry Companies|
Sponsored Financial Commentaries
To contact EMERGENT BIOSOLUTIONS INC, please visit www.emergentbiosolutions.com. Company data is provided by Capital IQ. Please use this form to report any data issues.